Synopsis
Synopsis
0
VMF
0
Australia
0
South Africa
US Medicaid
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ah 19065
2. Ah-19065
3. Ah19065
4. Biotidin
5. Hydrochloride, Ranitidine
6. N (2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine
7. Ranisen
8. Ranitidin
9. Ranitidine
10. Ranitidine Hydrochloride
11. Sostril
12. Zantac
13. Zantic
1. Ranitidine Hydrochloride
2. 66357-59-3
3. 71130-06-8
4. Fendibina
5. Gastridina
6. Gastrolav
7. Kuracid
8. Raniberl
9. Ranibloc
10. Alquen
11. Rani-nerton
12. Zantac
13. Nu-ranit
14. Rani-q
15. Ranitidine (hydrochloride)
16. Santanol
17. Tanidina
18. Toriol
19. Coralen
20. Quantor
21. Radin
22. Chebi:8777
23. Gastrial
24. Raniben
25. Ranibeta
26. Azantac
27. Zantac (tn)
28. (e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;hydrochloride
29. Mfcd00941509
30. {2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}[(z)-1-(methylamino)-2-nitroethenyl]amine Hydrochloride
31. Smr000653467
32. (e)-n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n-methyl-2-nitroethene-1,1-diamine
33. N-(2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)-n'-methyl-2-nitrovinylidenediamine Monohydrochloride
34. C13h22n4o3s.hcl
35. Zantic
36. Zantac;noctone
37. Sr-01000075288
38. Ah19065
39. Ah-19065
40. Prestwick_635
41. Einecs 275-207-4
42. Ranitidine (zantac)
43. Ranitidine Hydrochloride 100 Microg/ml In Acetonitrile
44. Epitope Id:127516
45. Mls001146938
46. Mls002548856
47. Chembl1092473
48. Hy-b0281a
49. Hms1568j03
50. Amy24712
51. Bcp28420
52. N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine Hydrochloride
53. N-[2-[5-[(dimethylamino)methyl]furfurylthio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine Hydrochloride
54. Tox21_501073
55. S1801
56. Ranitidine Hydrochloride (jp17/usp)
57. Akos015895250
58. Ccg-212946
59. Lp01073
60. Nc00479
61. Ranitidine For Impurity A Identification
62. Ncgc00094351-01
63. Ncgc00261758-01
64. Ac-12743
65. N-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-n'-methyl-2-nitroethene-1,1-diamine Hydrochloride
66. Eu-0101073
67. R-101
68. R0073
69. Sw196800-3
70. Bim-0051043.0001
71. D00673
72. 357n593
73. A835435
74. Sr-01000075288-2
75. W-104534
76. (e)-n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n'-methyl-2-nitroethene-1,1-diamine Hydrochloride
77. (e)-n1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-n1-methyl-2-nitroethene-1,1-diamine Hydrochloride
78. (e)-n1'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-n1-methyl-2-nitro-ethene-1,1-diamine Hydrochloride
79. 1,1-ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-, Hydrochloride
80. N-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n'-methyl-2-nitroethene-1,1-diamine Hydrochloride
81. N-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n-methyl-2-nitroethene-1,1-diaminehydrochloride
82. N-(2-((5-(dimethylaminomethyl)furan-2-yl)methylsulfanyl)ethyl)-n'-methyl-2-nitroethene-1,1-diamine Hcl
83. N-[2-[[[5-[(dimethylamino)methyl]-2 -furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-e Thanediamine Hydrochloride
Molecular Weight | 350.87 g/mol |
---|---|
Molecular Formula | C13H23ClN4O3S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 9 |
Exact Mass | 350.1179395 g/mol |
Monoisotopic Mass | 350.1179395 g/mol |
Topological Polar Surface Area | 112 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 347 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 10 | |
---|---|
Drug Name | Ranitidine hydrochloride |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet; Syrup; Capsule; Injectable |
Route | Injection; Oral |
Strength | eq 150mg base; eq 15mg base/ml; eq 75mg base; 25mg/ml; eq 300mg base; eq 25mg base/ml |
Market Status | Over the Counter; Prescription |
Company | Vintage Pharms; Amneal Pharms; Wockhardt; Silarx; Breckenridge Pharm; Teva; Pharm Assoc; Apotex; Torpharm; Shasun Chems; Taro; Sandoz; Par Pharm; Perrigo R And D; Svads Holdings Sa; Glenmark Generics; Amneal Pharms Ny; Ivax Sub Teva Pharms; Hi Tech Pharma |
2 of 10 | |
---|---|
Drug Name | Zantac |
PubMed Health | Ranitidine (Injection) |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2... |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Syrup; Injectable |
Route | Injection; Oral |
Strength | eq 15mg base/ml; eq 25mg base/ml |
Market Status | Prescription |
Company | Covis Injectables; Glaxo Grp |
3 of 10 | |
---|---|
Drug Name | Zantac 150 |
PubMed Health | Ranitidine |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2... |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 150mg base |
Market Status | Over the Counter; Prescription |
Company | Boehringer Ingelheim; Glaxo Grp |
4 of 10 | |
---|---|
Drug Name | Zantac 300 |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 300mg base |
Market Status | Prescription |
Company | Glaxo Grp |
5 of 10 | |
---|---|
Drug Name | Zantac 75 |
Drug Label | The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2... |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 75mg base |
Market Status | Over the Counter |
Company | Boehringer Ingelheim |
6 of 10 | |
---|---|
Drug Name | Ranitidine hydrochloride |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet; Syrup; Capsule; Injectable |
Route | Injection; Oral |
Strength | eq 150mg base; eq 15mg base/ml; eq 75mg base; 25mg/ml; eq 300mg base; eq 25mg base/ml |
Market Status | Over the Counter; Prescription |
Company | Vintage Pharms; Amneal Pharms; Wockhardt; Silarx; Breckenridge Pharm; Teva; Pharm Assoc; Apotex; Torpharm; Shasun Chems; Taro; Sandoz; Par Pharm; Perrigo R And D; Svads Holdings Sa; Glenmark Generics; Amneal Pharms Ny; Ivax Sub Teva Pharms; Hi Tech Pharma |
7 of 10 | |
---|---|
Drug Name | Zantac |
PubMed Health | Ranitidine (Injection) |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2... |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Syrup; Injectable |
Route | Injection; Oral |
Strength | eq 15mg base/ml; eq 25mg base/ml |
Market Status | Prescription |
Company | Covis Injectables; Glaxo Grp |
8 of 10 | |
---|---|
Drug Name | Zantac 150 |
PubMed Health | Ranitidine |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2... |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 150mg base |
Market Status | Over the Counter; Prescription |
Company | Boehringer Ingelheim; Glaxo Grp |
9 of 10 | |
---|---|
Drug Name | Zantac 300 |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 300mg base |
Market Status | Prescription |
Company | Glaxo Grp |
10 of 10 | |
---|---|
Drug Name | Zantac 75 |
Drug Label | The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2... |
Active Ingredient | Ranitidine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 75mg base |
Market Status | Over the Counter |
Company | Boehringer Ingelheim |
Histamine H2 Antagonists
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10998
Submission : 1994-08-25
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11480
Submission : 1995-04-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10989
Submission : 1994-07-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11543
Submission : 1995-06-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10885
Submission : 1994-04-25
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8494
Submission : 1990-03-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10516
Submission : 1993-10-05
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-15
Pay. Date : 2013-12-09
DMF Number : 8288
Submission : 1989-11-17
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8953
Submission : 1991-01-29
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7528
Submission : 1988-06-14
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
40
PharmaCompass offers a list of Ranitidine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ranitidine Hydrochloride manufacturer or Ranitidine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ranitidine Hydrochloride manufacturer or Ranitidine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ranitidine Hydrochloride API Price utilized in the formulation of products. Ranitidine Hydrochloride API Price is not always fixed or binding as the Ranitidine Hydrochloride Price is obtained through a variety of data sources. The Ranitidine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ranitidine HCL manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ranitidine HCL, including repackagers and relabelers. The FDA regulates Ranitidine HCL manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ranitidine HCL API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ranitidine HCL manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ranitidine HCL supplier is an individual or a company that provides Ranitidine HCL active pharmaceutical ingredient (API) or Ranitidine HCL finished formulations upon request. The Ranitidine HCL suppliers may include Ranitidine HCL API manufacturers, exporters, distributors and traders.
click here to find a list of Ranitidine HCL suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ranitidine HCL DMF (Drug Master File) is a document detailing the whole manufacturing process of Ranitidine HCL active pharmaceutical ingredient (API) in detail. Different forms of Ranitidine HCL DMFs exist exist since differing nations have different regulations, such as Ranitidine HCL USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ranitidine HCL DMF submitted to regulatory agencies in the US is known as a USDMF. Ranitidine HCL USDMF includes data on Ranitidine HCL's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ranitidine HCL USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ranitidine HCL suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ranitidine HCL Drug Master File in Japan (Ranitidine HCL JDMF) empowers Ranitidine HCL API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ranitidine HCL JDMF during the approval evaluation for pharmaceutical products. At the time of Ranitidine HCL JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ranitidine HCL suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ranitidine HCL Drug Master File in Korea (Ranitidine HCL KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ranitidine HCL. The MFDS reviews the Ranitidine HCL KDMF as part of the drug registration process and uses the information provided in the Ranitidine HCL KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ranitidine HCL KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ranitidine HCL API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ranitidine HCL suppliers with KDMF on PharmaCompass.
A Ranitidine HCL CEP of the European Pharmacopoeia monograph is often referred to as a Ranitidine HCL Certificate of Suitability (COS). The purpose of a Ranitidine HCL CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ranitidine HCL EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ranitidine HCL to their clients by showing that a Ranitidine HCL CEP has been issued for it. The manufacturer submits a Ranitidine HCL CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ranitidine HCL CEP holder for the record. Additionally, the data presented in the Ranitidine HCL CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ranitidine HCL DMF.
A Ranitidine HCL CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ranitidine HCL CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ranitidine HCL suppliers with CEP (COS) on PharmaCompass.
A Ranitidine HCL written confirmation (Ranitidine HCL WC) is an official document issued by a regulatory agency to a Ranitidine HCL manufacturer, verifying that the manufacturing facility of a Ranitidine HCL active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ranitidine HCL APIs or Ranitidine HCL finished pharmaceutical products to another nation, regulatory agencies frequently require a Ranitidine HCL WC (written confirmation) as part of the regulatory process.
click here to find a list of Ranitidine HCL suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ranitidine HCL as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ranitidine HCL API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ranitidine HCL as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ranitidine HCL and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ranitidine HCL NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ranitidine HCL suppliers with NDC on PharmaCompass.
Ranitidine HCL Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ranitidine HCL GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ranitidine HCL GMP manufacturer or Ranitidine HCL GMP API supplier for your needs.
A Ranitidine HCL CoA (Certificate of Analysis) is a formal document that attests to Ranitidine HCL's compliance with Ranitidine HCL specifications and serves as a tool for batch-level quality control.
Ranitidine HCL CoA mostly includes findings from lab analyses of a specific batch. For each Ranitidine HCL CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ranitidine HCL may be tested according to a variety of international standards, such as European Pharmacopoeia (Ranitidine HCL EP), Ranitidine HCL JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ranitidine HCL USP).